An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
LANCASTER, Calif.--(BUSINESS WIRE)--
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be participating in BTIG’s MedTech, Digital Health, Life Science and Diagnostic Tools Conference, taking place virtually from February 15-17, 2022.
Shawn O’Connor, chief executive officer, will present on Tuesday, February 15, 2022, at 3:30 p.m. ET. In addition, Mr. O’Connor will also be available to host one-on-one meetings throughout the day. To listen to the live event or request a one-on-one meeting, please contact your BTIG representative. The Company’s slide presentation will be available on the investors page of the Simulations Plus website following the BTIG presentation.
For more information about the BTIG conference, please visit the BTIG website or contact Brian Siegel from Hayden IR at brian@haydenir.com.
About Simulations Plus
Serving clients worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | LinkedIn.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
